نوع مقاله : مقاله مروری
نویسندگان
1 کارشناس پژوهشی، مرکز تحقیقات جامعنگر عملکرد گوارش، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران
2 دانشیار، گروه علوم تشریح و بیولوژی مولکولی، دانشکدهی پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران
3 دانشیار، گروه آندرولوژی و جنینشناسی، مرکز تحقیقات پزشکی تولید مثل، پژوهشکدهی زیست فناوری جانوری رویان اصفهان، اصفهان، ایران
4 استاد، بخش گوارش، گروه بیماریهای داخلی، مرکز تحقیقات جامعنگر عملکرد گوارش، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران.
چکیده
کلیدواژهها
عنوان مقاله [English]
نویسندگان [English]
Background: Stem cells are undifferentiated cells that can turn into any number of differentiated and specific cell types. For years, stem cell assisted therapy has been accepted as a standard treatment method for the management of some diseases. Scientists hope that this method can be expanded and used for the treatment of other diseases. One of the main concerns in the field of stem cell therapy research is the safety of these cells. This article assessed the safety of using mesenchymal fibroblasts, keratinocytes, melanocytes and skeletal myoblasts in clinical trials.Methods: A systematic search of reliable electronic databases was performed in order to find all articles related to safety of the mentioned cells. After studying all the articles critically, the preliminary results were reviewed and criticized by experts through Delphi method. Ultimately, the final draft was reviewed and approved by all the members of the Regional Research Ethics Committee.Findings: Overall, 62 articles were retrieved and studied. Conclusion: Since we did not find any reports of serious complications for fibroblast, keratinocyte and melanocyte cells, especially about their in-vivo uncontrolled proliferation, it is possible to give ethical approval for research in these fields (considering all ethical codes and principles). However, according to serious complications reported for skeletal myoblast cells transplantation, giving ethical approval for using this cell type in human research requires strict commitment to precise methods (such as inclusion criteria, patient follow-up methods, and prophylactic treatments). The ethical approval should be issued by the research ethics committee of the corresponding university after accurate reviews. Finally, repeating previous research which has resulted in arrhythmia and tissue injury is unethical and thus not recommended.
کلیدواژهها [English]